Balance Sheet Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Pharmaceuticals

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 03:34:10 2025-07-16 am EDT			5-day change	1st Jan Change
1.300 ^ILa	0.00%		+8.33%	-31.58%

Jun. 16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	CI
May. 05	Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson	RE

1196e35bb2f7d2eeb3e4ea.FXfSE64aw0pLPf4HuHO3I2J6g0ktX-SjKtqOwYIZijw.ZjrhV_lSuyl7fptX1yHlSFoP0yFpaKPUYKu9pe40uXpSMJ0j90CUOShKkQ

Published financial data: CAN-FITE BIOPHARMA LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	763K	853K	810K	743K	674K
Total Revenues	763K	853K	810K	743K	674K
Gross Profit	763K	853K	810K	743K	674K
Selling General & Admin Expenses, Total	2.95M	3.84M	3.14M	2.96M	3.05M
R&D Expenses	11.95M	9.85M	7.76M	5.98M	5.76M
Other Operating Expenses, Total	14.9M	13.7M	10.91M	8.94M	8.8M
Operating Income	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
Interest Expense, Total	-363K	-4K	-	-	-
Interest And Investment Income	44K	24K	222K	506K	291K
Net Interest Expenses	-319K	20K	222K	506K	291K
Currency Exchange Gains (Loss)	28K	59K	-54K	58K	-13K
Other Non Operating Income (Expenses)	-24K	-14K	-16K	-14K	-14K
EBT, Excl. Unusual Items	-14.45M	-12.78M	-9.94M	-7.64M	-7.87M
Gain (Loss) On Sale Of Investments	11K	162K	-229K	11K	-14K
Gain (Loss) On Sale Of Assets	-	-	-	-	-
EBT, Incl. Unusual Items	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Income Tax Expense	-	-	-	-	-
Earnings From Continuing Operations	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Net Income to Company	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Minority Interest	-	-	-	-	-
Net Income - (IS)	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Preferred Dividend and Other Adjustments	715K	2.59M	-	-	-
Net Income to Common Incl Extra Items	-15.16M	-15.2M	-10.17M	-7.63M	-7.88M
Net Income to Common Excl. Extra Items	-15.16M	-15.2M	-10.17M	-7.63M	-7.88M
Per Share Items
Net EPS - Basic	-0.04	-0.03	-0.01	-0.01	-0
Basic EPS - Continuing Operations	-0.04	-0.03	-0.01	-0.01	-0
Basic Weighted Average Shares Outstanding	358M	553M	816M	1.28B	2.18B
Net EPS - Diluted	-0.04	-0.03	-0.01	-0.01	-0
Diluted EPS - Continuing Operations	-0.04	-0.03	-0.01	-0.01	-0
Diluted Weighted Average Shares Outstanding	358M	553M	816M	1.28B	2.18B
Normalized Basic EPS	-0.03	-0.01	-0.01	-0	-0
Normalized Diluted EPS	-0.03	-0.01	-0.01	-0	-0
American Depositary Receipts Ratio (ADR)	300	300	300	300	300
Supplemental Items
EBITDA	-14.13M	-12.83M	-10.08M	-8.18M	-8.12M
EBITA	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
EBIT	-14.14M	-12.84M	-10.1M	-8.2M	-8.13M
EBITDAR	-14.08M	-12.77M	-10.03M	-8.12M	-8.08M
Effective Tax Rate - (Ratio)	-	-	-	-	-
Normalized Net Income	-9.03M	-7.99M	-6.22M	-4.78M	-4.92M
Interest on Long-Term Debt	-	-	-	-	-
Non-Cash Pension Expense	-	-	-	47K	49K
Supplemental Operating Expense Items
General and Administrative Expenses	2.95M	3.84M	3.14M	2.96M	3.05M
Research And Development Expense From Footnotes	11.95M	9.85M	7.76M	5.98M	5.76M
Net Rental Expense, Total	43K	55K	54K	56K	44K
Imputed Operating Lease Interest Expense	1.76M	18.43K	-	-	-
Imputed Operating Lease Depreciation	-1.72M	36.57K	-	-	-
Stock-Based Comp., R&D Exp. (Total)	159K	200K	137K	83K	75K
Stock-Based Comp., G&A Exp. (Total)	158K	198K	126K	178K	287K
Stock-Based Comp., Other (Total)	38K	68K	-	-	-
Total Stock-Based Compensation	355K	466K	263K	261K	362K

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	8.27M	4.39M	2.98M	4.28M	4.82M
Short Term Investments	-	14.51M	5M	4.62M	3.06M
Trading Asset Securities, Total	75K	237K	8K	19K	-
Total Cash And Short Term Investments	8.34M	19.14M	7.99M	8.92M	7.89M
Other Receivables	18K	-	-	-	-
Total Receivables	18K	-	-	-	-
Prepaid Expenses	1.04M	881K	1.12M	908K	1.02M
Other Current Assets, Total	-	48K	47K	78K	77K
Total Current Assets	9.4M	20.07M	9.16M	9.91M	8.98M
Gross Property Plant And Equipment	343K	419K	374K	344K	190K
Accumulated Depreciation	-220K	-234K	-248K	-263K	-52K
Net Property Plant And Equipment	123K	185K	126K	81K	138K
Long-term Investments	-	-	-	-	-
Other Long-Term Assets, Total	-	-	-	-	-
Total Assets	9.52M	20.25M	9.28M	9.99M	9.12M
Liabilities
Accounts Payable, Total	561K	954K	896K	427K	618K
Accrued Expenses, Total	331K	905K	775K	944K	976K
Current Portion of Leases	43K	53K	48K	27K	53K
Unearned Revenue Current, Total	334K	818K	783K	622K	405K
Total Current Liabilities	1.27M	2.73M	2.5M	2.02M	2.05M
Long-Term Leases	24K	71K	14K	13K	51K
Unearned Revenue Non Current	2.16M	3.07M	2.3M	1.71M	1.58M
Pension & Other Post Retirement Benefits	-	-	-	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	3.45M	5.87M	4.81M	3.75M	3.68M
Common Stock, Total	33.04M	60.65M	-	-	-
Additional Paid In Capital	97.38M	93.28M	154M	164M	171M
Retained Earnings	-125M	-141M	-151M	-158M	-166M
Treasury Stock	-	-	-	-	-
Comprehensive Income and Other	1.13M	1.13M	1.13M	1.13M	1.13M
Total Common Equity	6.07M	14.38M	4.47M	6.24M	5.44M
Minority Interest	-	-	-	-	-
Total Equity	6.07M	14.38M	4.47M	6.24M	5.44M
Total Liabilities And Equity	9.52M	20.25M	9.28M	9.99M	9.12M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	516M	816M	1.22B	1.5B	3.11B
ECS Total Common Shares Outstanding	464M	816M	816M	1.36B	2.98B
Book Value / Share	0.01	0.02	0.01	0	0
Tangible Book Value	6.07M	14.38M	4.47M	6.24M	5.44M
Tangible Book Value Per Share	0.01	0.02	0.01	0	0
Total Debt	67K	124K	62K	40K	104K
Net Debt	-8.28M	-19.02M	-7.92M	-8.88M	-7.78M
Debt Equivalent of Unfunded Proj. Benefit Obligation	-	-	-	-	-
Debt Equivalent Oper. Leases	344K	440K	432K	448K	352K
Minority Interest, Total (Incl. Fin. Div)	-	-	-	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	257K	268K	277K	279K	79K
Full Time Employees	8	8	8	8	5

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-14.44M	-12.62M	-10.17M	-7.63M	-7.88M
Depreciation & Amortization - CF	12K	14K	14K	15K	7K
Depreciation & Amortization, Total	12K	14K	14K	15K	7K
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-11K	-162K	229K	-11K	14K
Stock-Based Compensation (CF)	355K	466K	263K	261K	362K
Other Operating Activities, Total	1.57M	-46K	167K	-128K	127K
Change In Accounts Receivable	2.73M	-	-	-	-
Change In Accounts Payable	-1.6M	393K	-58K	-469K	191K
Change in Unearned Revenues	-401K	1.4M	-810K	-743K	-349K
Change in Other Net Operating Assets	-278K	694K	-433K	269K	-109K
Cash from Operations	-12.06M	-9.86M	-10.8M	-8.44M	-7.64M
Capital Expenditure	-26K	-11K	-9K	-2K	-5K
Sale of Property, Plant, and Equipment	-	-	-	-	-
Divestitures	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-	-14.5M	9.51M	500K	1.5M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-26K	-14.51M	9.5M	498K	1.5M
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	17.68M	20.46M	-	9.53M	7.22M
Other Financing Activities, Total	-	-	-	-386K	-512K
Cash from Financing	17.68M	20.46M	-	9.14M	6.71M
Foreign Exchange Rate Adjustments	-23K	34K	-113K	98K	-22K
Net Change in Cash	5.57M	-3.88M	-1.41M	1.3M	547K
Supplemental Items
Cash Interest Paid	23K	30K	-	-	-
Cash Income Tax Paid (Refund)	-	-	-	-	-
Levered Free Cash Flow	-7.41M	-5.98M	-6.51M	-5.12M	-4.82M
Unlevered Free Cash Flow	-7.18M	-5.98M	-6.51M	-5.12M	-4.82M
Change In Net Working Capital	-1.32M	-1.58M	464K	277K	103K
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-99.87	-53.91	-42.73	-53.15	-53.18
Return on Total Capital	-204.13	-77.75	-66.28	-94.7	-85.96
Return On Equity %	-339.2	-123.34	-107.91	-142.49	-134.94
Return on Common Equity	-355.99	-148.66	-107.91	-142.49	-134.94
Margin Analysis
Gross Profit Margin %	100	100	100	100	100
SG&A Margin	386.76	450.76	388.02	397.71	452.08
EBITDA Margin %	-1.85K	-1.5K	-1.24K	-1.1K	-1.21K
EBITA Margin %	-1.85K	-1.51K	-1.25K	-1.1K	-1.21K
EBIT Margin %	-1.85K	-1.51K	-1.25K	-1.1K	-1.21K
Income From Continuing Operations Margin %	-1.89K	-1.48K	-1.26K	-1.03K	-1.17K
Net Income Margin %	-1.89K	-1.48K	-1.26K	-1.03K	-1.17K
Net Avail. For Common Margin %	-1.99K	-1.78K	-1.26K	-1.03K	-1.17K
Normalized Net Income Margin	-1.18K	-936.18	-767.28	-643.09	-729.41
Levered Free Cash Flow Margin	-970.61	-701.14	-803.21	-689.75	-715.17
Unlevered Free Cash Flow Margin	-940.87	-700.85	-803.21	-689.75	-715.17
Asset Turnover
Asset Turnover	0.09	0.06	0.05	0.08	0.07
Fixed Assets Turnover	6.33	5.54	5.21	7.18	6.16
Short Term Liquidity
Current Ratio	7.41	7.35	3.66	4.9	4.38
Quick Ratio	6.59	7.01	3.19	4.42	3.84
Operating Cash Flow to Current Liabilities	-9.51	-3.61	-4.32	-4.18	-3.72
Long Term Solvency
Total Debt/Equity	1.1	0.86	1.39	0.64	1.91
Total Debt / Total Capital	1.09	0.85	1.37	0.64	1.88
LT Debt/Equity	0.4	0.49	0.31	0.21	0.94
Long-Term Debt / Total Capital	0.39	0.49	0.31	0.21	0.92
Total Liabilities / Total Assets	36.22	28.99	51.83	37.5	40.39
EBIT / Interest Expense	-38.95	-3.21K	-	-	-
EBITDA / Interest Expense	-38.8	-3.19K	-	-	-
(EBITDA - Capex) / Interest Expense	-38.87	-3.2K	-	-	-
Total Debt / EBITDA	-0	-0.01	-0.01	-0	-0.01
Net Debt / EBITDA	0.59	1.49	0.79	1.09	0.96
Total Debt / (EBITDA - Capex)	-0	-0.01	-0.01	-0	-0.01
Net Debt / (EBITDA - Capex)	0.59	1.49	0.79	1.09	0.96
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-62.45	11.8	-5.04	-8.27	-9.29
Gross Profit, 1 Yr. Growth %	-62.45	11.8	-5.04	-8.27	-9.29
EBITDA, 1 Yr. Growth %	17.79	-9.2	-21.41	-18.87	-0.7
EBITA, 1 Yr. Growth %	17.76	-9.17	-21.38	-18.83	-0.79
EBIT, 1 Yr. Growth %	17.76	-9.17	-21.38	-18.83	-0.79
Earnings From Cont. Operations, 1 Yr. Growth %	14.4	-12.66	-19.36	-24.96	3.22
Net Income, 1 Yr. Growth %	14.4	-12.66	-19.36	-24.96	3.22
Normalized Net Income, 1 Yr. Growth %	16.41	-11.6	-22.17	-23.12	2.89
Diluted EPS Before Extra, 1 Yr. Growth %	-71.22	-35	-54.64	-52.12	-39.36
Net Property, Plant and Equip., 1 Yr. Growth %	4.24	50.41	-31.89	-35.71	70.37
Total Assets, 1 Yr. Growth %	16.5	112.67	-54.16	7.61	-8.7
Tangible Book Value, 1 Yr. Growth %	148.73	136.78	-68.91	39.6	-12.93
Common Equity, 1 Yr. Growth %	148.73	136.78	-68.91	39.6	-12.93
Cash From Operations, 1 Yr. Growth %	8.83	-18.28	9.57	-21.86	-9.51
Capital Expenditures, 1 Yr. Growth %	766.67	-57.69	-18.18	-77.78	150
Levered Free Cash Flow, 1 Yr. Growth %	-2.9	-19.24	8.78	-21.23	-5.94
Unlevered Free Cash Flow, 1 Yr. Growth %	-2.47	-16.72	8.83	-21.23	-5.94
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-55.31	-35.21	3.03	-6.67	-8.78
Gross Profit, 2 Yr. CAGR %	-55.31	-35.21	3.03	-6.67	-8.78
EBITDA, 2 Yr. CAGR %	61.74	3.42	-15.52	-20.15	-10.24
EBITA, 2 Yr. CAGR %	61.6	3.42	-15.5	-20.12	-10.26
EBIT, 2 Yr. CAGR %	61.6	3.42	-15.5	-20.12	-10.26
Earnings From Cont. Operations, 2 Yr. CAGR %	48.26	-0.04	-16.07	-22.21	-11.99
Net Income, 2 Yr. CAGR %	48.26	-0.04	-16.07	-22.21	-11.99
Normalized Net Income, 2 Yr. CAGR %	56.22	1.44	-17.06	-22.65	-11.06
Diluted EPS Before Extra, 2 Yr. CAGR %	-49.96	-56.75	-45.7	-53.4	-46.11
Net Property, Plant and Equip., 2 Yr. CAGR %	61.77	25.21	1.21	-33.83	4.65
Total Assets, 2 Yr. CAGR %	9.43	57.41	-1.27	-29.77	-0.88
Tangible Book Value, 2 Yr. CAGR %	41.94	142.68	-14.19	-34.11	10.25
Common Equity, 2 Yr. CAGR %	41.94	142.68	-14.19	-34.11	10.25
Cash From Operations, 2 Yr. CAGR %	70.39	-5.69	-5.38	-7.47	-15.91
Capital Expenditures, 2 Yr. CAGR %	-11.24	91.49	-41.17	-57.36	-25.46
Levered Free Cash Flow, 2 Yr. CAGR %	67.95	-11.45	-6.27	-7.41	-13.92
Unlevered Free Cash Flow, 2 Yr. CAGR %	74.46	-9.88	-4.8	-7.41	-13.92
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-1.11	-39.33	-26.4	-0.88	-7.55
Gross Profit, 3 Yr. CAGR %	-1.11	-39.33	-26.4	-0.88	-7.55
EBITDA, 3 Yr. CAGR %	25.39	33.43	-5.62	-16.65	-14.13
EBITA, 3 Yr. CAGR %	25.31	33.36	-5.61	-16.62	-14.13
EBIT, 3 Yr. CAGR %	25.31	33.36	-5.61	-16.62	-14.13
Earnings From Cont. Operations, 3 Yr. CAGR %	30.94	24.28	-6.95	-19.15	-14.52
Net Income, 3 Yr. CAGR %	31.59	24.28	-6.95	-19.15	-14.52
Normalized Net Income, 3 Yr. CAGR %	27.23	29.21	-7.13	-19.13	-14.93
Diluted EPS Before Extra, 3 Yr. CAGR %	-39.91	-45.4	-56.06	-47.93	-49.12
Net Property, Plant and Equip., 3 Yr. CAGR %	63.78	57.89	2.21	-13	-9.31
Total Assets, 3 Yr. CAGR %	7.74	36.56	4.33	1.61	-23.35
Tangible Book Value, 3 Yr. CAGR %	6.6	68.34	22.34	0.92	-27.7
Common Equity, 3 Yr. CAGR %	6.6	68.34	22.34	0.92	-27.7
Cash From Operations, 3 Yr. CAGR %	10.37	33.37	-0.86	-11.22	-8.16
Capital Expenditures, 3 Yr. CAGR %	54.87	-30.66	44.22	-57.47	-23.11
Levered Free Cash Flow, 3 Yr. CAGR %	3.13	31.58	-5.16	-11.55	-6.93
Unlevered Free Cash Flow, 3 Yr. CAGR %	2.06	36.34	-4.03	-10.63	-6.93
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	36.33	38.9	0.53	-27.92	-19.81
Gross Profit, 5 Yr. CAGR %	36.33	38.9	0.53	-27.92	-19.81
EBITDA, 5 Yr. CAGR %	16.94	8.13	7.07	8.66	-7.5
EBITA, 5 Yr. CAGR %	16.9	8.11	7.04	8.64	-7.5
EBIT, 5 Yr. CAGR %	16.9	8.11	7.04	8.64	-7.5
Earnings From Cont. Operations, 5 Yr. CAGR %	17.28	8.49	9.6	3.04	-9
Net Income, 5 Yr. CAGR %	18.26	8.85	9.92	3.04	-9
Normalized Net Income, 5 Yr. CAGR %	18.92	9.42	7.22	5.24	-8.72
Diluted EPS Before Extra, 5 Yr. CAGR %	-31.08	-37.92	-42.3	-48.75	-52.32
Net Property, Plant and Equip., 5 Yr. CAGR %	15.22	35.84	35.1	11.5	3.18
Total Assets, 5 Yr. CAGR %	-11.59	14.77	4.04	4.67	2.21
Tangible Book Value, 5 Yr. CAGR %	-10.08	19.43	-2.26	15.67	17.36
Common Equity, 5 Yr. CAGR %	-10.08	19.43	-2.26	15.67	17.36
Cash From Operations, 5 Yr. CAGR %	20.16	2.5	3.78	15.23	-7.18
Capital Expenditures, 5 Yr. CAGR %	-9.15	1.92	5.15	-42.92	10.76
Levered Free Cash Flow, 5 Yr. CAGR %	16.78	2.77	-0.74	14.31	-8.77
Unlevered Free Cash Flow, 5 Yr. CAGR %	16.05	2.76	-0.74	16.79	-8.12